oftioconazole Cream 1% versus
|
|
- Juniper Norris
- 5 years ago
- Views:
Transcription
1 The Journal ofinternational Medical Research 1987; IS: 2~3l Comparative and Non-comparative Studies ofthe Efficacy and Tolerance oftioconazole Cream 1% versus Another Imidazole and/or Placebo in Neonates and Infants with Candidal Diaper Rash and/or Impetigo D. L. Gibbs, P. Kashin and S. Jevons Medical Division, Pfizer International, 235 East 42nd Street, New York, NY10017, USA Eleven open multicentre studies were conducted to evaluate the efficacy of tioconazole cream 1% as a treatment for diaper rash with or without fungal (Candida) involvement, or impetigo in neonates and infants. In the dermal /diaper rash group, 320 patients had either tioconazole (n = 220), a comparative imidazole (n = 43), or vehicle cream (n = 57) applied to the affected area twice daily. Twenty-one impetigo patients had only tioconazole cream 1% applied three times daily to lesions. The overall cure rate (patients with both clinical and mycological cure) at the end of treatment for tioconazole treated patients was 78%, for the comparative imidazole group it was 76% and for vehicle cream it was At the long-term follow-up evaluation approximately 6 weeks after treatment for patients with diaper rash, the overall cure rate was about the same in both tioconazole- and comparative imidazole-treated patients (87% and 90%, respectively), and 14% in patients using vehicle cream. Sideeffects were coincident with disease symptoms and consisted primarily of erythema localized to the treatment area; they occurred in 5.4% (13/241) of the patients who received tioconazole and in 21% (9/43) of the patients who received comparative imidazole (econazole or miconazole). No side-effects were reported in this open study for the 57 patients who used vehicle cream. The results of these studies show that tioconazole cream 1% is safe and effective for the treatment of neonates and infants with dermal, diaper rash and impetigo. Received for publication 21 October 1986; accepted 30 October Address for correspondence: Dr. D. L. Gibbs, Medical Division, Pfizer International Inc., 235 East 42nd Street, New York, NY 10017, USA. ccopyright 1987 by Cambridge Medical Publications Ltd. 23
2 N.,.. 0 r Table 1 0 6' DistnDution ofpatients sr J" :-a No. ofpatients treated p Vehicle ~ Investigator Country Indication Tioconazole Imidazoles4' cream Total... (II Dr. J. C. Badoual and France Neonatal and infantile Prof. E. Drouhet Prof. R. Gilly France Neonatal and infantile Dr. D. Grigoriu Switzerland Neonatal and infantile Dr. D. Grigoriu Switzerland Neonatal and infantile Dr. E. Haneke West Germany Neonatal and infantile Prof. Z. Itani West Germany Neonatal and infantile Prof. R. M. MacKie Scotland Neonatal and infantile Dr. L. Stimmler UK Neonatal and infantile Dr. L. Stimmler UK Neonatal and infantile Prof. C. F. H. Vickers UK Neonates and infants with fungal infection Prof. J. Maleville France Impetigo ;;0::: I'> '" cr. < 0 ::3 '" Total Comparative imidazoles included miconazole and econazole.
3 Efficacy and tolerance of tioconazole cream rtzz: INTRODUCTION (Trosyd'"), an imidazole derivative, has proven to be a potent broad spectrum anti-fungal agent that also has in vitro activity against certain Gram-positive bacteria'r' both in laboratory evaluations and in the clinical treatment of dermal fungal infections! and vaginal.' The majority of patients treated so far have been adults, and this study was established to investigate the safety and efficacy of topically applied tioconazole dermal cream 1% in the treatment of very young patients. The clinical conditions treated were primarily dermal (predominantly diaper rash) and impetigo. Diaper rash is a clinical condition with various causative factors including overhydration, friction, detergents, disinfectants and faeces. Dermal is rarely found in infants with normal skin but is reported to occur in 40-75% of those with diaper rash. 5 6 Where intense erythema in groin folds and perianal skin is evident, the recovery rate of Candida albicans may be as high as 80%.7 ~ Registered Trade Mark of Pfizer InternationalInc. This report presents the findings of 11 European open multicentre clinical trials (five comparative and six noncomparative) on patients with diaper rash and/or culture-positive superficial Candida or Gram-positive bacterial infections. PATIENTS AND METHODS The 11 studies investigated a total of 341 patients with dermal or diaper rash and impetigo (21 patients in one study). The dermal /diaper rash studies were conducted by nine investigators in France, Switzerland, West Germany, Scotland and England. One investigator in France investigated impetigo (Table l). Of the 341 patients studied, 241 (71%) used tioconazole dermal cream 1%,43 patients (13%) used a comparative imidazole (37 used econazole and six used miconazole) and 57 patients (17%) used a vehicle cream (Table 2). Patients with mycologically proven candidal infections and/or diaper rash were included in the efficacy assessment. In the impetigo study, patients whose clinical diagnosis was confirmed microbiologically were included in the efficacy assessment. Informed consent Table 2 Summary ofpatients by infection category and treatment group No. of patients treated Type of infection Tioconazole Econazole Miconazole Vehicle cream Total Dermal /diaper rash Impetigo Total
4 D. L. Gibbs, P. Kashin, S.Jevons 26 from patients' parents or legal guardian was obtained. Patients requiring other anti-fungal or antibiotic therapy (systemic antibiotic therapy in the impetigo group) and patients receiving treatment with any other investigational drugs were excluded. All patients had their clinical histories taken and were given a physical examination. In the /diaper rash group, swabs or scrapings of the infected skin were taken prior to treatment. Part of the specimen was examined microscopically and part was cultured on Sabourad agar plates. In the impetigo group, specimens for Gram staining and culture were obtained from the lesions. Minimum inhibitory concentrations (MICs) of tioconazole were determined. Although review times varied, in most of the /diaper rash studies reviews were performed every 7 days during treatment and again at the end of treatment. In patients who were clinically cured, a follow-up review was conducted approximately 6 weeks after completion of treatment to determine whether or not relapse or re-infection had occurred. Impetigo patients were reviewed every 3-4 days after the start of treatment. For all patients, each review entailed clinical assessments of the signs and symptoms of infection, independent of mycological or bacteriological findings. Clinical response to treatment was graded as 'cured', 'improved' or 'treatment failure'. Mycological examinations by microscopy and culture were performed at all reviews in the majority of studies. Note was made of the time required to bring about symptom relief and to clear the lesions clinically. Criteriafor efficacy evaluation A clinical cure was achieved if there was complete resolution of the signs and symptoms of infection, and clearing of lesions from the affected area. Improvement required considerable resolution of the signs and symptoms, and treatment failure occurred if the condition remained unchanged or worsened. Mycological cures were based on microscopy showing the absence of yeast in skin scrapings from the affected area(s) and on culture results showing the absence of fungal growth in standard media. Drug administration Tioconazole dermal cream 1% and the comparative agents were supplied in identical 30 g tubes. All active agents were supplied as a 1% cream. In the /diaper rash group, the cream was applied to the affected area(s) thinly and evenly, and rubbed in gently twice daily in the majority of cases for up to 28 days. In the impetigo group, infected areas were bathed three times daily by swabbing with warm water for approximately 10 min. Debris was removed and the lesions dried prior to tioconazole application. Tioconazole was applied liberally to the lesions and rubbed in gently three times daily for up to 21 days. Treatment was stopped if the rash worsened or an increased irritation occurred. Safety At each review, a record was made of the nature, severity, time of onset, course, duration and any symptomatic treatment of observed side-effects. RESULTS A total of 341 in- and out-patients were included in the 11 studies: 241 were treated with tioconazole dermal cream 1%; 43 were randomized to a compara-
5 Efficacy and tolerance of tioconazole cream Table 3 Patient demographics: age distribution Group 1 Candidiasis/diaper rash Group 2t Impetigo Age ranges Comparative Vehicle (months) Tioconazole imidazole cream Tloconazole Patients (%) <I > Total Group 1 consisted of all patients treated for and/or diaper rash. t Group 2 consisted of all patients treated for impetigo. tive imidazole (econazole, 37 patients; miconazole, six patients); and 57 were assigned to the vehicle cream. Patients were pooled into two groups for purposes of analysis: group 1 included the /diaper rash patients (n = 320), and group 2 included the impetigo patients (n = 21). Patient ages in group 1 ranged from 3 days to 14 years; the majority were 1 year or less. In group 2 (impetigo patients), ages ranged from 21 months to 14 years; 12 patients were older than 3 years and the rest were between 1 and 3 years (fable 3). The majority of patients in both groups were between 3 and 12 months old. In group I (/diaper rash), Table 4 Mycological diagnoses of all /diaper rash patients (group I) No. of patients Comparative Vehicle Pathogen Tioconazole imidazole cream Total Patients (%) Candida spp C. albicans C. parapsilosis I C. tropicalis Unidentified microscopy Patients without fungal involvement No culture/microscopy 20 I 2 2~ 7.2 Total IOO.v 27
6 D. L. Gibbs, P. Kashin, S. Jevons Table S Bacteriological diagnoses ofall impetigo patients (group 2) Pathogen Staphylococcus aureus Streptococci S. aureus + Streptococci S. aureus + Gram-negative bacilli S. aureus + Streptococci + Enterobacter Acinetobacter Not identified Total No. of patients Patients (%) % (248/320) of patients had dermal with confirmed Candida as the infecting organism (Table 4). Of the remaining 72 patients in group I, 65% (47/72) did not have a candidal infection while 0.6% had unidentified microscopy. Histological data were missing for 32% of the patients. In one study, three patients were concomitantly infected with Staphylococcus, aureus. The diaper and adjacent areas were the primary sites of infection in the majority of candidal patients. 'Impetigo was diagnosed at 34 sites in the 21 patients in this group. Bacteriological diagnoses for these patients are shown in Table 5. Sites of infection involved the limbs, head and body. Staphylococcus aureus was identified as the sole organism in 38% of the infection sites and, together with other organisms, was found in 43% of the sites. Other infecting organisms included Gram-negative bacilli, Enterobacter and Acinetobacter In group 1 (/diaper rash), 93 patients were excluded from the efficacy analysis and four patients were excluded from group 2 (impetigo group). These patients were excluded due to default and/or lack of mycological or bacteriological data. Efficacy Table 6 summarizes the mean duration of therapy for all patients in each treatment group: 15 days for tioconazole, 19 days for comparative imidazoles and 12 days for the vehicle cream. For impetigo patients, the mean duration of tioconazole therapy was 8.5 days. Candidal diaper rash patients were clinically and mycologically assessed at the end of treatment and again at followup (approximately 6 weeks after treatment). Table 7 shows the clinical and mycological response rates, and the candidal patients who exhibited both clinical and mycological cures (overall cure) at the end of treatment and at the long-term follow-up. At the end of treatment, 78% of tioconazole-treated patients were cured overall compared with 76% of patients given comparative imidazoles and 26% of patients given vehicle cream. Of the patients seen at follow-up who were cured at the end of treatment, 86% of tioconazole-treated patients remained cured. In the study comparing tioconazole to vehicle cream in treating diaper rash patients with and without fungal involvement, clinical cure rates at the end of treatment in patients with fungal involvement were 78% for
7 Efficacy and tolerance of tioconazole cream Table 6 Mean duration oftherapy Treatment duration (days) Group 1 Candidiasis/diaper rash Group 2 Impetigo Tioconazole (n=220) Comparative imidazole (n=43) Vehicle cream (n=51) Tioconazole (n=21) Mean Range Patients with <1 day of treatment o Patients with I day of treatment or less are not included in the mean duration (includes one tioconazole-treated candida!patient who had no duration recorded). tioconazole-treated patients and 39% for vehicle cream-treated patients (P<O.Ol). In patients with no fungal involvement, tioconazole and vehicle cream were equally effective (tioconazole, 68%; vehicle cream, 71%). Seventeen impetigo patients were assessed clinically and bacteriologically at the end of treatment and follow-up (Table 8). At the end of treatment, a clinical cure was seen in 71% (12/17) of patients; 47% (8/17) of patients were bacteriologically cured. Of the patients seen at follow-up, all remained cured. Tolerance Side-effects were coincident with disease symptoms and occurred in 5% (13/241) of the tioconazole-treated patients who Table 7 Clinical and mycological response rates at the end of treatment and after 6 weeks' posttreatment follow-up for patients with candidal diaper rash" End oftreatment Follow-up Overall CUnically cure End oftreatment cured or Mycologically (clinical and Overall cures who remained Treatment Improved cured mycological) cure cured at fouow-up Tioconazole 142/ / /147 77/89 70/81 (90) (92) (78) (87) (86) Comparative 39/41 28/37 28/37 28/31 28/28 imidazole (95) (76) (76) (90) (100) Vehicle cream 11/28 9/23 6/23 1/7 1/1 (39) (39) (26) (14) (100) Valuesin parentheses are percentages. 29
8 D. L. Gibbs, P. Kashin, S. Jevons Table 8 Clinical and bacterial response rates at the end of treatment and follow-up for patients with impetigo End of treatment Overall cure Clinical Bacterial (clinical and Treatment cure cure bacterial) Tioconazole 12/17 8/17 8/17 (71) (47) (47) Overall cure 8/8 (100) Follow-up End of treatment cures who remained cured at fouow-up 6/6 (100) Values in parentheses are percentages. had 17 treatment-related side-effects. In the comparative imidazole treatment group, 21% (9/43) of the patients experienced 13 treatment-related sideeffects. The most frequently reported side-effect in all treatment groups was erythema, localized to the treatment area. Eight patients were withdrawn from the study because of drug-related side-effects, seven (3%) in the tioconazole group and one (2%) in the comparative imidazole group. No side-effects were experienced by any patients treated with the vehicle cream. DISCUSSION Diaper rash is a common condition with no well defined aetiology or treatment. Suggested management varies from palliative methods, such as exposure to air, to treatment with barrier creams and non-specific anti-microbial agents. The treatment of fungal skin and vaginal yeast infections with topically applied tioconazole is a widely accepted and successful form of therapy. The 11 studies reported here assessed the benefit of anti-fungal therapy by comparing the efficacy of tioconazole, the comparative imidazole creams econazole and miconazole, and vehicle cream in the treatment of diaper rash with and without fungal involvement. The incidence of fungal involvement in diaper rash was shown to be 56% in one study (Stimmler); Candida was the infecting organism in the majority of cases. In patients with proven fungal involvement, 78% were clinically cured with tioconazole, whereas vehicle cream resulted in clinical success in only 39% of patients. The difference in cure rates was significant (P< 0.01). In diaper rash patients without fungal involvement, both tioconazole and vehicle creams were effective with no difference between cure rates. It was concluded from this study (Stimmler) that. while treatment of diaper rash with tioconazole was beneficial with or without mycological confirmation of infection, vehicle cream was only effective in the group without evidence of candidal involvement. In the remainder of the studies, with the exception of one for impetigo, the majority of patients were treated with tioconazole or comparative imidazole creams for mycologically proven of the skin, predominantly diaper rash. The pooled results for all patients with mycologically proven infection again showed tioconazole to be highly effective in the treatment of this condition; 78% of patients were clinically and mycologically cured at the 30
9 Efficacy and tolerance of tioconazole cream end of treatment. This cure rate was similar to that seen with the comparative imidazoles (76%), econazole and miconazole, although the small number of patients treated with other imidazoles precludes any statistical comparison. The incidence of side-effects associated with tioconazole was markedly lower than comparative imidazoles and side-effects were all local. The incidence and nature of the sideeffects in this study were similar to those seen in much larger numbers of adult patients treated with tioconazole dermal cream. It is concluded that tioconazole cream 1% is a safe and effective treatment for infants and neonates with fungal infection of the skin. ACKNOWLEDGEMENT The assistance of Ms. Rosemarie T. Eccleston in the preparation of the manuscript is gratefully acknowledged. REFERENCES I. Jevons S, Gymer GE, Brammer KW, et al: Antifungal activity of tioconazole (UK-20, 349), a new imidazole derivative. Antimicrob Agents Chemother 1979; 15: Marriott MS, Baird JCR, Brammer KW, et al: Tioconazole, a new antifungal agent for the treatment of dermatomycoses. Dermatologica 1983; l66(suppll): East O'Neill M, Henderson JT, Jevons S: Tioconazole in the treatment of fungal infections of the skin. Dermatologica 1983; 166(suppll): Henderson JT, Neilson W, Wilson AB, et al: Tioconazole in the treatment of vaginal. Gynakof Rundsch 1983; 23(suppll): Dixon PN, Warin RP, English MP: Role of Candida albicans infections in napkin rashes. Br Med J 1969; 2: Montes LF, Pittillo RP, Hunt D, et al: Microbial flora of infants skin: comparison of types of micro-organisms between normal skin and diaper dermatitis. Arch Dermatol 1971; 103: Leyden JJ, Kligman AM: The role of microorganisms in diaper dermatitis. Arch Dermatol 1978; 114:
Introduction. Study of fungi called mycology.
Fungi Introduction Study of fungi called mycology. Some fungi are beneficial: ex a) Important in production of some foods, ex: cheeses, bread. b) Important in production of some antibiotics, ex: penicillin
More informationCANDIDIASIS (WOMEN) Single Episode. Clinical Features. Diagnosis. Management
CANDIDIASIS (WOMEN) What s new: Section on Management of Vulvovaginal Non-Albicans Candida Infection in Adults approved by GGC antimicrobial team Routine candida sensitivity testing has been discontinued,
More informationNORLAND AVENUE PHARMACY PRESCRIPTION COMPOUNDING FOR GENERAL PRACTICE
OCTOBER 2011 NORLAND AVENUE PHARMACY PRESCRIPTION COMPOUNDING N ORLANDA VENUEP HARMACY. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: Smoking Cessation
More informationWe customize individual prescriptions for the specific needs of our patients.
We customize individual prescriptions for the specific needs of our patients. J A N U A R Y 2 0 1 3 I N S I D E T H I S I S S U E : Vulvodynia 2 Vulvovaginal Candidiasis Breastfeeding Challenges 3 4 P
More informationTOUGH ON IMPETIGO GENTLE ON THE1 PATIENT. Demonstrated efficacy and safety1. New treatment option now available!
New treatment option now available! TOUGH ON IMPETIGO GENTLE ON THE1 PATIENT Demonstrated efficacy and safety1 Home Efficacy Safety Convenience (ozenoxacin) is indicated for the topical treatment of impetigo
More informationdida tropicalis, Candida parapsilosis, Candida krusei, Cr. neoformans
dida tropicalis, Candida parapsilosis, Candida krusei, Cr. neoformans Key words: Susceptibility test, IC99, miconazole, fluconazole, itraconazole, Micro-dilution method, 96-multiwell plate Table 1. Cunteffis
More informationStaphylococci. Gram stain: gram positive cocci arranged in clusters.
Microbiology lab Respiratory system Third medical year Lab contents: Gram positive bacteria (Staphylococcus and Streptococcus spp), two types of filamentous fungi (Aspergillus and Penicillium spp), and
More informationDesitin for yeast infections
Desitin for yeast infections Search Some Desitin For Yeast Infection What Is A Yeast Extract Yeast Infection On Vulva Skin and look into preventative measures if it is easy to have for treatment of. Find
More informationTypes of Skin Infections
Anatomy of Skin Types of Skin Infections Bacterial Impetigo Folliculitis Acne Fungal /Parasitic Tinea Pedis Tinea Cruris Tinea Versicolor Tinea Corporis Toenail fungus Allergic/Irritation conditions Dermatitis
More informationOral fluconazole 150 mg single dose versus intra-vaginal clotrimazole treatment of acute vulvovaginal candidiasis
Journal of Infection and Public Health (2011) 4, 195 199 150 mg single dose versus intra-vaginal treatment of acute vulvovaginal candidiasis Leila Sekhavat, Afsarosadat Tabatabaii, Fatemah Zare Tezerjani
More informationNEW ZEALAND DATA SHEET PEVARYL 1% w/w Foaming Solution
1 PRODUCT NAME PEVARYL 1% w/w foaming solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Econazole nitrate 1.0% w/w (as econazole base) Excipients with known effect: Benzyl alcohol For a full list of
More informationMicrobiology products. Liofilchem Chromatic
ET Microbiology products M IC R O PL A N www.liofilchem.net Liofilchem Chromatic c h ro m o g e n i c c u l t u re m e d i a LIOFILCHEM s.r.l. Via Scozia, Zona Industriale 64026 Roseto degli Abruzzi (Te)
More informationEvaluation of in Vitro Antifungal Activity of Ketoconazole and Griseofulvin
Evaluation of in Vitro Antifungal Activity of Ketoconazole and Griseofulvin Abstract Pages with reference to book, From 230 To 234 Taj B. Uppal ( Department of Pathology Khyber Medical College, Peshawar.
More informationEffect of Antimicrobial Soap Containing Chlorhexidine on the
APPLIED AND ENVIRONMENTAL MICROBIOLOGY, June 1976, p. 931-935 Copyright 1976 American Society for Microbiology Vol. 31, No. 6 Printed in U.S.A. Effect of Antimicrobial Soap Containing Chlorhexidine on
More informationStaphylococcus aureus is the most common bacterial agent of the skin flora of patients with seborrheic dermatitis
DERMATOLOGY PRACTICAL & CONCEPTUAL www.derm101.com Staphylococcus aureus is the most common bacterial agent of the skin flora of patients with seborrheic dermatitis Funda Tamer 1, Mehmet Eren Yuksel 2,
More informationSUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT Fusidic Acid 2% Cream SUMMARY OF PRODUCT CHARACTERISTICS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 2 % cream. Each gram contains 20 mg fusidic acid. Excipient(s) with
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More information1 / 9. والحشفة القلفة التهاب= Balanoposthitis
1 / 9 والحشفة القلفة التهاب= Balanoposthitis Balanoposthitis Defined as the inflammation of the foreskin and glans in uncircumcised males, balanoposthitis occurs over a wide age range and may have any
More informationAmruta Mohite 1, Anil Gugle 2*, Rahul Kote 3 and Vikrant Jadhav 4
MVP Journal of Medical Sciences, Vol 2(2), 76-80, July-December 2015 A Comparative Study of Efficacy, Safety and Relapse Rate of Three Drugs; Systemic Ketoconazole, Systemic Itraconazole and Topical Oxiconazole
More informationPrescribing Information
Prescribing Information Pr DERMOVATE Cream (clobetasol propionate cream, USP) Pr DERMOVATE Ointment (clobetasol propionate ointment, USP) Topical corticosteroid TaroPharma Preparation Date: A Division
More informationMicafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013
Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version 1.0 5 February 2013 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised
More informationWhat s New. Vaginal Discharge Protocol. History
What s New Information has been added on interpreting vaginal scoring system and AV scores. Vaginal Discharge Protocol History Low risk STI PLUS Typical BV or VVC history AND No symptoms of PID High risk
More informationInternational Journal of Scientific & Engineering Research, Volume 7, Issue 8, August ISSN
International Journal of Scientific & Engineering Research, Volume 7, Issue 8, August-2016 105 Antimicrobial activity of Andrographis paniculata stem extracts. S.Gurupriya 1 and Dr.L.Cathrine 2 1 M.phil
More informationRoutine endotracheal cultures for the prediction of sepsis in ventilated babies
Archives of Disease in Childhood, 1989, 64, 34-38 Routine endotracheal cultures for the prediction of sepsis in ventilated babies T A SLAGLE, E M BIFANO, J W WOLF, AND S J GROSS Department of Pediatrics,
More informationCandida albicans 426 (64.0 ) C. albicans non-albicans
74 2006 1) 2) 1) 3) 4) 5) 6) 1) 2) 3) 4) 5) 6) 17 9 26 18 3 8 2003 10 2004 3 6 9,083 666 (7.3 ) Candida albicans 426 (64.0 ) C. albicans non-albicans 233 (35.0 ) Non-albicans Candida glabrata Candida tropicalis
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationCommon Superficial Fungal Infections
How to recognise and treat Common Superficial Fungal Infections Dr Lilianne Scholtz (MBBCh) Types of superficial fungal infections Ringworm (Tinea) Candida (Thrush) Body Groin Feet Skin Nappy rash Vagina
More informationInt.J.Curr.Res.Aca.Rev.2017; 5(9): 10-14
International Journal of Current Research and Academic Review ISSN: 2347-3215 (Online) Volume 5 Number 9 (September-2017) Journal homepage: http://www.ijcrar.com doi: https://doi.org/10.20546/ijcrar.2017.509.002
More informationDifferentiation between women with vulvovaginal symptoms who are positive or negative for Candida species by culture
Infect Dis Obstet Gynecol 2001;9:221 225 Differentiation between women with vulvovaginal symptoms who are positive or negative for species by culture Iara M. Linhares 1,2, Steven S. Witkin 2, Shirlei D.
More informationEvaluation of the feasibility of the VACUETTE Urine CCM tube for microbial testing of urine samples
Evaluation of the feasibility of the VACUETTE Urine CCM tube for microbial testing of urine samples Background The VACUETTE Urine CCM tube is for the collection, transport and storage of urine samples
More informationAction of Antifungal Imidazoles on Staphylococcus aureus
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 1982, p. 47 474 66-484/82/947-4$2./ Copyright 1982, American Society for Microbiology Vol. 22, No. 3 Action of Antifungal Imidazoles on Staphylococcus aureus
More informationGynofort (butoconazole nitrate) Vaginal Cream, 2.0%
Gynofort (butoconazole nitrate) Vaginal Cream, 2.0% Rx Only Decription Butoconazole Nitrate Vaginal Cream, 2.0% contains butoconazole nitrate 2%, an imidazole derivative with antifungal activity. Its chemical
More informationL. Montero. Carrera 16# , Consultorio 303, Santafe de Bogotd, D.C., Colombia
Journal of Antimicrobial Chemotherapy (1996) 37, Suppl. C, 125-131 A comparative study of the efficacy, safety and tolerability of azithromycin and cefaclor in the treatment of children with acute skin
More informationPREVALANCE OF CANDIDIASIS IN CHILDREN IN MUMBAI
Wandre et al., 2015 Volume 1 Issue 1, pp. 25-36 Year of Publication: 2015 DOI- https://dx.doi.org/10.20319/lijshls.2015.s11.2536 This paper can be cited as: Wandre, S., Sanap, S., Mukadam, T., Vaidya,
More informationRisk Factors for Acute Cellulitis of the Lower Limb: A Prospective Case-Control Study
MAJOR ARTICLE Risk Factors for Acute Cellulitis of the Lower Limb: A Prospective Case-Control Study Sigrídur Björnsdóttir, 1 Magnús Gottfredsson, 1,3 Anna S. Thórisdóttir, 1 Gunnar B. Gunnarsson, 1 Hugrún
More informationVoriconazole. Voriconazole VRCZ ITCZ
7 7 8 7 8 fluconazole itraconazole in vitro in vivo Candida spp. C. glabrata C. krusei Cryptococcus neoformans in vitro Aspergillus spp. in vitro in vivo Aspergillus fumigatus Candida albicans C. krusei
More informationCORTISPORIN Cream (neomycin and polymyxin B sulfates and hydrocortisone acetate cream, USP)
CORTISPORIN Cream (neomycin and polymyxin B sulfates and hydrocortisone acetate cream, USP) DESCRIPTION CORTISPORIN Cream (neomycin and polymyxin B sulfates and hydrocortisone acetate cream, USP) is a
More informationHealthcare-associated infections acquired in intensive care units
SURVEILLANCE REPORT Annual Epidemiological Report for 2015 Healthcare-associated infections acquired in intensive care units Key facts In 2015, 11 788 (8.3%) of patients staying in an intensive care unit
More informationEvaluation of Cefuroxime Axetil and Cefadroxil Suspensions
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 1992, p. 1614-1618 0066-4804/92/081614-05$02.00/0 Copyright 1992, American Society for Microbiology Vol. 36, No. 8 Evaluation of Cefuroxime Axetil and Suspensions
More informationInvestor Presentation December 2012
Investor Presentation December 2012 1 Safe Harbor Statement Certain items in this presentation and other matters discussed today or answers that may be given to questions asked could constitute forwardlooking
More informationOriginal Article Characterization of candida species isolated from cases of lower respiratory tract infection
Kathmandu University Medical Journal (2006), Vol. 4, No. 3, Issue 15, 290-294 Original Article Characterization of candida species isolated from cases of lower respiratory tract infection Jha BK 1, Dey
More informationMRSA: A TEAM APPROACH
Eric Bosley, MD Laura Stadler, MD John MD J h Draus, D MRSA: A TEAM APPROACH PART I: OUTPATIENT ISSUES AND MANAGEMENT NOT REQUIRING I&D OR HOSPITALIZATION Eric L. Bosley, MD, FAAP Pediatric Associates,
More informationOZONE EFFECTS ON SPECIFIC BACTERIA AND VIRUSES (
Bacterial infections and the spread of viruses relating to athletic gear are becoming a bigger concern each year. Numerous articles are being written and public awareness is growing rapidly to the health
More informationPrevalence and Management of Non-albicans Vaginal Candidiasis
Prevalence and Management of Non-albicans Vaginal Candidiasis Nalin Hetticarachchi, Ruth Ashbee, Janet D Wilson To cite this version: Nalin Hetticarachchi, Ruth Ashbee, Janet D Wilson. Prevalence and Management
More informationNOVASTREAK. Microbial Contamination Monitoring Device TYPICAL CULTURAL MORPHOLOGY Baird Parker Agar. S. aureus growth on Baird Parker Agar
NOVASTREAK Microbial Contamination Monitoring Device TYPICAL CULTURAL MORPHOLOGY Baird Parker Agar S. aureus growth on Baird Parker Agar Baird Parker Agar is used for the selective isolation and enumeration
More informationBlood culture 壢新醫院 病理檢驗科 陳啟清技術主任
Blood culture 壢新醫院 病理檢驗科 陳啟清技術主任 A Positive Blood Culture Clinically Important Organism Failure of host defenses to contain an infection at its primary focus Failure of the physician to effectively eradicate,
More informationVoriconazole Rationale for the EUCAST clinical breakpoints, version March 2010
Voriconazole Rationale for the EUCAST clinical breakpoints, version 2.0 20 March 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationKelly H. Tyler, MD, FACOG, FAAD S052 Gender Dermatology: Diagnosis and Treatment of Genital Skin Disorders Vulvar Dermatitis
Vulvar Dermatitis Kelly H. Tyler, MD, FACOG, FAAD Assistant Professor The Ohio State University Department of Internal Medicine, Division of Dermatology Department of Obstetrics and Gynecology Center for
More informationPREVALANCE OF CANDIDIASIS IN CHILDREN IN MUMBAI
Shrutika Wandre et al. Special Issue, 2015, pp. 25-36 PREVALANCE OF CANDIDIASIS IN CHILDREN IN MUMBAI Shrutika Wandre Department of Clinical Pathology, Haffkine Institute for Training, Research and Testing,
More information320 MBIO Microbial Diagnosis. Aljawharah F. Alabbad Noorah A. Alkubaisi 2017
320 MBIO Microbial Diagnosis Aljawharah F. Alabbad Noorah A. Alkubaisi 2017 Blood Culture What is a blood culture? A blood culture is a laboratory test in which blood is injected into bottles with culture
More information320 MBIO Microbial Diagnosis. Aljawharah F. Alabbad Noorah A. Alkubaisi 2017
320 MBIO Microbial Diagnosis Aljawharah F. Alabbad Noorah A. Alkubaisi 2017 Pathogens of the Urinary tract The urinary system is composed of organs that regulate the chemical composition and volume of
More informationIJBCP International Journal of Basic & Clinical Pharmacology
Print ISSN 2319-2003 Online ISSN 2279-0780 IJBCP International Journal of Basic & Clinical Pharmacology doi: 10.18203/2319-2003.ijbcp20150020 Research Article Efficacy safety of 1% terbinafine hydrochloride
More information6. SUMMARY AND CONCLUSION
6. SUMMARY AND CONCLUSION Infectious diseases are one of man s oldest enemies. They continue to be a serious burden around the world, in developing and industrialised countries alike. It is said that every
More informationClassification. Distal & Lateral Subungual OM. White Superficial OM. Proximal Subungual OM. Candidal OM. Total dystrophic OM
Onychomycosis Commonest dermatological condition Definition: Infection of the nail caused by fungi that include dermatophytes, non-dermatophyte moulds and yeasts (mainly Candida). 80% of all OM affects
More information5-Fluorocytosine resistance in clinical isolates of cryptococcus neoformans
Med. J. Malaysia Vol. 44 No. 3 September 1989 5-Fluorocytosine resistance in clinical isolates of cryptococcus neoformans C.S. Chin, B Se (Hons) Y.M. Cheong, MBBS, M Se Bacteriology Division Institute
More informationComparison of the efficacy and safety of oral fluconazole and topical clotrimazole in patients
98 Outpatients' Center for Diagnosis of Infectious Disease, Vienna, Austria A Stary Ludwig-Baltzmann Institute for Research of Infectious Diseases, Vienna, Austria J Soeltz-Szoets C Ziegler Royal Hallamshire
More informationPrevalence of Oral Thrush Yeasts among School Children with special emphasis of Fluconazole antifungal drug
International Journal of Current Research in Medical Sciences ISSN: 2454-5716 P-ISJN: A4372-3064, E -ISJN: A4372-3061 www.ijcrims.com Original Research Article Volume 3, Issue 3-2017 DOI: http://dx.doi.org/10.22192/ijcrms.2017.03.03.016
More informationCandida auris: an Emerging Hospital Infection
National Center for Emerging and Zoonotic Infectious Diseases Candida auris: an Emerging Hospital Infection Paige Armstrong MD MHS Epidemic Intelligence Service Officer Mycotic Diseases Branch Association
More informationRx only FOR TOPICAL DERMATOLOGIC USE ONLY, NOT FOR OPHTHALMIC, ORAL, OR INTRAVAGINAL USE
STZC:R1 ERTACZO TM (SERTACONAZOLE NITRATE) CREAM, 2% Rx only FOR TOPICAL DERMATOLOGIC USE ONLY, NOT FOR OPHTHALMIC, ORAL, OR INTRAVAGINAL USE DESCRIPTION: ERTACZO TM (sertaconazole nitrate) Cream, 2%,
More informationAn Update in the Management of Candidiasis
An Update in the Management of Candidiasis Daniel B. Chastain, Pharm.D., AAHIVP Infectious Diseases Pharmacy Specialist Phoebe Putney Memorial Hospital Adjunct Clinical Assistant Professor UGA College
More informationDiscrepancies in the recovery of bacteria from multiple sinuses in acute and chronic sinusitis
Journal of Medical Microbiology (2004), 53, 879 885 DOI 10.1099/jmm.0.45655-0 Short Communication Correspondence Itzhak Brook ib6@georgetown.edu Received 1 March 2004 Accepted 18 May 2004 Discrepancies
More informationLab 4. Blood Culture (Media) MIC AMAL-NORA-ALJAWHARA 1
Lab 4. Blood Culture (Media) 2018 320 MIC AMAL-NORA-ALJAWHARA 1 Blood Culture 2018 320 MIC AMAL-NORA-ALJAWHARA 2 What is a blood culture? A blood culture is a laboratory test in which blood is injected
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER Clotrimazole Cream 1%
PACKAGE LEAFLET PACKAGE LEAFLET: INFORMATION FOR THE USER Clotrimazole Cream 1% Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
More informationRashes Not To Be Missed In Children
May 2016 Rashes Not To Be Missed In Children Dr Chan Yuin Chew Dermatologist Dermatology Associates Gleneagles Medical Centre Scope of presentation Focus on rashes May lead to significant morbidity if
More informationPrescribing Information. Taro-Clobetasol. Taro-Clobetasol
Prescribing Information Pr Taro-Clobetasol Clobetasol Propionate Cream USP, 0.05% w/w Pr Taro-Clobetasol Clobetasol Propionate Ointment USP, 0.05% w/w Therapeutic Classification Topical corticosteroid
More informationCeftizoxime in the treatment of infections in patients with cancer
Journal of Antimicrobial Chemotherapy (98), Suppl. C, 67-73 Ceftizoxime in the treatment of infections in patients with cancer V. Fainstein, R. Bolivar,. Elting, M. Valdivieso and G. P. Bodey Department
More informationTherapeutics for the Clinician
Luliconazole for the Treatment of Interdigital Tinea Pedis: A Double-blind, Vehicle-Controlled Study Michael Jarratt, MD; Terry Jones, MD; Steven Kempers, MD; Phoebe Rich, MD; Katy Morton; Norifumi Nakamura,
More informationSummary of Product Characteristics
Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT Terbinafine Dermapharm, 10 mg/g, cream 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One gram of cream contains 10 mg of terbinafine hydrochloride.
More informationClarithromycin versus penicillin in the treatment of streptococcal pharyngitis
Journal of Antimicrobial Chemotherapy (1991) 27, Suppl. A, 67-74 Clarithromycin versus penicillin in the treatment of streptococcal pharyngitis Joseph H. Levenstein* South Africa Academy of Family Practice,
More information16.9 hours. Not reported 19.9 hours. Metabolism: Not known Elimination: Not known. Efficacy:
Brand Name: Luzu Generic Name: luliconazole Manufacturer 1 : Medicis Pharmaceutical Corporation Drug Class 1,2,3,4 : Imidazole antifungal, topical Uses Labeled Uses 1,2,3,4 : Topical treatment of interdigital
More informationDifference Between Seborrheic Dermatitis and Psoriasis
Difference Between Seborrheic Dermatitis and Psoriasis www.differencebetween.com Key Difference Seborrheic Dermatitis vs Psoriasis Dermatological conditions are perhaps the most worrisome diseases in the
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory ZODERM E CREAM. Oxiconazole Nitrate Cream
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory ZODERM E CREAM Oxiconazole Nitrate Cream QUALITATIVE AND QUANTITATIVE COMPOSITION ZODERM E CREAM contains: Oxiconazole
More informationStudy of Nasal Mucosal Flora in Acute and Chronic Sinusitis
Study of Nasal Mucosal Flora in Acute and Chronic Sinusitis Rupeshkumar TS 1, Rajesh K 2, Prabhusaran N 3*, Jesudoss A 4 Original Research Article 1MBBS Student, 2Associate Professor, 4 Professor & Head,
More informationOpportunistic Mycoses
CANDIDIASIS SOFYAN LUBIS DEPARTEMEN MIKROBIOLOGI FAK.KEDOKTERAN USU MEDAN 2009 Opportunistic Mycoses Opportunistic mycoses are fungal infections that do not normally cause disease in healthy people, but
More informationComparison of Superficial Mycosis treatment using Butenafine and Bifonazole nitrate Clinical Efficacy
Global Journal of Health Science; Vol. 5, No. 1; 2013 ISSN 1916-9736 E-ISSN 1916-9744 Published by Canadian Center of Science and Education Comparison of Superficial Mycosis treatment using Butenafine
More informationComparative study of the disinfection capacity of different floor cleaning solutions on ventilated room floor
Comparative study of the disinfection capacity of different floor cleaning solutions on ventilated room floor M. G. Sanal Kumar, S. Nandakumar, B. Bini & Arya Raj R. S. P.G. & Research Department of Zoology,
More informationCytolytic vaginosis: misdiagnosed as candidal vaginitis
Infect Dis Obstet Gynecol 2004;12:13 16 : misdiagnosed as candidal vaginitis Nilgun Cerikcioglu 1 and M. Sinan Beksac 2 1 Department of Microbiology, Marmara University School of Medicine, Turkey 2 Gynecology
More informationA class IIa medical device intended for mild-to-moderate fungal nail infection PRODUCT MONOGRAPH
A class IIa medical device intended for mild-to-moderate fungal nail infection PRODUCT MONOGRAPH AWB-2052628721 Date of Preparation March 2017 Introduction to Bayer Bayer is a Life Science company with
More informationBioprospecting of Neem for Antimicrobial Activity against Soil Microbes
ISSN: 2454-132X Impact factor: 4.295 (Volume3, Issue1) Available online at: www.ijariit.com Bioprospecting of Neem for Antimicrobial Activity against Soil Microbes R. Prasanna PRIST University, Tamilnadu
More informationSputum Screening by Nomarski Interference Contrast
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 1979, p. 520-524 0095-1137/79/04-0520/05$02.00/0 Vol. 9, No. 4 Sputum Screening by Nomarski Interference Contrast Microscopy DAVID F. WELCH AND MICHAEL T. KELLYt*
More informationTable 1. Antifungal Breakpoints for Candida. 2,3. Agent S SDD or I R. Fluconazole < 8.0 mg/ml mg/ml. > 64 mg/ml.
AUSTRALIAN ANTIFUNGAL SUSCEPTIBILITY DATA 2008-2011 Part 1: The Yeasts In this article, an update of recent changes to the CLSI antifungal standards for susceptibility testing of yeasts is presented. We
More informationGYNAZOLE 1 (butoconazole nitrate) vaginal cream 2%
GYNAZOLE 1 (butoconazole nitrate) vaginal cream 2% Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan.
More informationENG MYCO WELL D- ONE REV. 1.UN 29/09/2016 REF. MS01283 REF. MS01321 (COMPLETE KIT)
ENG MYCO WELL D- ONE MYCO WELL D-ONE System for the presumptive identification and antimicrobial susceptibility test of urogenital mycoplasmas, Gardnerella vaginalis, Trichomonas vaginalis, Candida albicans
More informationVulvovaginal Candidiasis
Vulvovaginal Candidiasis Hope K. Haefner, MD Michigan Medicine Ann Arb, MI USA Make Your Selection 1 Your Diagnosis Is? A. Candida albicans infection B. Non albicans Candida infection C. Gonrhea D. None
More information!Microbiology Profile, stool
LAB #: F000000-0000-0 PATIENT: Sample Patient ID: P12345 SEX: Female AGE: 37 CLIENT #: 12345 DOCTOR: Doctor's Data, Inc. 3755 Illinois Ave. St. Charles, IL 60174!Microbiology Profile, stool BACTERIOLOGY
More informationFungal Resistance, Biofilm, and Its Impact In the Management of Nail Infection
Fungal Resistance, Biofilm, and Its Impact In the Management of Nail Infection Faculty Raza Aly, PhD, MPH Professor Emeritus University of California Medical Center (MSSF) Professor, Dermatology Faculty
More informationTrichophyton Microsporum Epidermophyton. dermatomycosis. Dematiaceous(pigmented fungi ) Dimorphic fungi Yeast and yeast like saprophyte
Cutaneous candidiasis dermatophytosis Trichophyton Microsporum Epidermophyton dermatomycosis Dematiaceous(pigmented fungi ) Dimorphic fungi Yeast and yeast like saprophyte dermatomycosis Yeast & yeast
More informationCERTIFICATE OF ACCREDITATION
CERTIFICATE OF ACCREDITATION In terms of section 22(2) (b) of the Accreditation for Conformity Assessment, Calibration and Good Laboratory Practice Act, 2006 (Act 19 of 2006), read with sections 23(1),
More informationActivity of TDT 067 (Terbinafine in Transfersome) against Agents of Onychomycosis, as Determined by Minimum Inhibitory and Fungicidal Concentrations
JOURNAL OF CLINICAL MICROBIOLOGY, May 2011, p. 1716 1720 Vol. 49, No. 5 0095-1137/11/$12.00 doi:10.1128/jcm.00083-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Activity of
More informationIncontinence Associated Dermatitis. Moisture Associated Dermatitis 8/31/2017. Goals of Presentation. Differentiating and Controlling
Incontinence Associated Dermatitis Moisture Associated Dermatitis Differentiating and Controlling Goals of Presentation This presentation will attempt to: Identify causes and risk factors for IAD and MASD
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article A Case Study of the Incidence and Risk Factors of Vaginal Candidiasis in a Girl s Senior High
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Microbiology Department Crawley Hospital West Green Drive Crawley RH11 7DH United Kingdom Contact: Clare Reynolds Tel: +44 (0) 1293 600379
More informationVISHALKSHI VISHWANATH AND NITI KHUNGER
Indian J.Sci.Res. 6(1) : 11-15, 2015 AN OBSERVATIONAL, COMPARATIVE STUDY TO ASSESS THE EFFICACY AND SAFETY OF TOPICAL CLOTRIMAZOLE CREAM 1% AND MICONAZOLE GEL 2% IN DERMATOPHYTOSES IN REAL LIFE CLINICAL
More informationWHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS?
WHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS? Assoc. Prof. Dr. Serkan SENER Acibadem University Medical School Department of Emergency Medicine, Istanbul Acibadem Ankara Hospital,
More informationEvaluation of Antibacterial Effect of Odor Eliminating Compounds
Evaluation of Antibacterial Effect of Odor Eliminating Compounds Yuan Zeng, Bingyu Li, Anwar Kalalah, Sang-Jin Suh, and S.S. Ditchkoff Summary Antibiotic activity of ten commercially available odor eliminating
More informationVimta Labs Ltd., Life Sciences Facility, Plot No. 5, Alexandria Knowledge Park, Genome Valley, Shameerpet, Hyderabad, Telangana
Last Amended on - Page 1 of 14 I. DRUGS & PHARMACEUTICALS 1. Biological Assays Antibiotics And Other Drugs Bulk Drugs & Their Formulations: Erythromycin, Gentamicin, Nystatin IP Appendix 9.1 2.2.10 BP
More informationAUSTRALIAN PRODUCT INFORMATION RESOLVE PLUS 1.0 (MICONAZOLE NITRATE, HYDROCORTISONE) CREAM
AUSTRALIAN PRODUCT INFORMATION RESOLVE PLUS 1.0 (MICONAZOLE NITRATE, HYDROCORTISONE) CREAM 1 NAME OF THE MEDICINE Miconazole nitrate, Hydrocortisone. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Miconazole
More informationOUTLINE Laboratory Detection and Reporting of Streptococcus agalactiae
OUTLINE Laboratory Detection and Reporting of Streptococcus agalactiae I. Importance of prenatal screening strategies II. Past approaches Erik Munson Clinical Microbiology Wheaton Franciscan Laboratory
More information